Global Cell and Advanced Therapies Supply Chain Management Market Strategic Research Report

Scope of the Report

The global Cell and Advanced Therapies Supply Chain Management market size is predicted to grow from US$ 1,037 million in 2025 to US$ 1,717 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.

Cell and Advanced Therapies Supply Chain Management is a systematic approach to resource planning, traceability, and compliance management for cell therapy, gene therapy, and tissue engineering products, encompassing the entire process from collection, production, cold chain transportation to final clinical application. It covers therapies including CAR-T, TCR-T, stem cells, oncolytic viruses, and gene editing products. Core management stages include: donor material collection and transportation, plasmid/viral vector production, cell engineering and amplification, quality control and release, liquid nitrogen cryogenic storage, and patient reinfusion. This supply chain must strictly adhere to GMP/GTP standards and achieve end-to-end cold chain temperature monitoring (-196°C to -80°C) and on-chain traceability (batch, chain identity). Dedicated supply chain software is typically used to interface with ERP and clinical trial systems and is applied by pharmaceutical companies, CROs/CDMOs, and advanced therapeutic hospitals. Its goal is to ensure product quality stability, reduce transportation losses, and achieve full compliance throughout the process.

market is dominated by North America, led by European standards, and experiencing accelerated manufacturing and clinical applications in the Asia-Pacific region. North America (primarily the US) boasts mature commercial products such as CAR-T, driven by capital investment in vertical SaaS and hardware integration. Europe emphasizes end-to-end compliance and data privacy, with SAP Life Sciences Solutions and MAK-SYSTEM focusing on GMP-level manufacturing and transportation traceability. EMA regulations are driving the demand for closed-loop management of advanced therapies in hospitals. The Asia-Pacific region (China, Japan, and South Korea) is experiencing a surge in cell therapy clinical pipelines and policy support, leading companies like Genscript, WuXi AppTec, and NIPRO to rapidly localize their supply chains and accelerate their integration into international chains. Future trends include end-to-end blockchain traceability, automated liquid nitrogen storage and delivery via IoT, and integration with electronic medical data for cell therapy. Obstacles include the stability risks of multi-temperature cold chains (-80°C to -196°C), extremely narrow time windows from single-collection to reinfusion, and a lack of globally recognized digital interoperability standards.

This report presents a comprehensive overview of the global Cell and Advanced Therapies Supply Chain Management market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Cloud
• On-premises

Segment by Supply Chain

• Collection
• Production and Manufacturing
• Cold Chain Transportation
• Storage
• Clinical Use
• Others

Segment by Temperature

• Ambient Temperature (15-25°C)
• Refrigerated (2-8°C)
• Frozen (-20°C)
• Deep-frozen (-80°C)
• Cryogenic Temperature (-196°C)

Segment by Application

• Biobank
• Cell Therapy Lab
• Hospital
• Research Institute
• Commercial Organization

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cell and Advanced Therapies Supply Chain Management market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Biobank, Cell Therapy Lab, Hospital evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact